Loading…

AtriCure, Inc.ATRCCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of devices for surgical treatment of atrial fibrillation and left atrial appendage exclusion, and pain management.

Momentum leader 95
Mkt cap
$2.82B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$47.8M
20-day average traded
Fwd P/E
212.4×
forward earnings
ROIC−WACC
-7.8 pp
WACC 11.0%
Hurdle
+33 pp
Req g minus delivered
Next earnings
97 days
23 Feb 2027
Close · USD$55.45
1D+0.8%
1W-3.6%
1M-3.9%
3M+16.8%
6M+91.2%
YTD+40.2%
1Y+67.4%
ATR %4.6%
Beta0.67
52w lowhigh16.0% off high

What AtriCure does

Maker of devices for surgical treatment of atrial fibrillation and left atrial appendage exclusion, and pain management.

Sells disposable devices to hospitals, used once per procedure, so revenue grows with the number of heart surgeries that use them. AtriClip, an implant that closes off a part of the heart where clots form, is the main line. Most sales are in the US.

Products and services

  • AtriClip left atrial appendage exclusion
  • Ablation devices (cryo/RF) for AFib
  • cryoSPHERE nerve-block pain management

Customers

  • Cardiac/cardiothoracic surgeons
  • Hospitals

Where it sits in the supply chain

  • Medical devices
  • Cardiac surgery devices
  • AFib ablation & left atrial appendage…

What could go right

  • Surgical AFib treatment adoption growth
  • Left atrial appendage exclusion guideline support

What could go wrong

  • Surgeon training/adoption curve
  • Competition from catheter-based ablation

Moat: narrow (IP / patents, installed base, switching costs). Category-leading AtriClip device with surgeon training and patented technology creates switching costs.

Headquarters: Mason, Ohio · Founded: 2000 · Employees: 1,350

Named competitors

AtriCure at a glance

Size AtriCure (ATRC) is a United States Health Care company (Medical Specialties) with a market value of $2.82B, the 1581st largest of 3,085 United States companies the cockpit tracks. Shares closed at $55.45 on 18 Nov 2026.

Performance Over six months the shares gained 91.2%, against -1.3% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 13.8% over the last twelve months (peer median +4.7%); the operating margin is 3.1% (peer median 8.3%).

Valuation It trades at 212.4× forward earnings against a peer median of 24.4× (most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 54% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +33 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 7.8 points below its cost of capital (11.0% WACC).

Short interest Short interest is 9.6% of the free float (30 Oct 2026).

Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026ATRC 192Peer median 100
Six months, rebased to 100: AtriCure against the median of its 20 peers (local-currency closes).

AtriCure financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$590M$535M$465M$399M$330M
Revenue growth—+15%+17%+21%—
Gross profit$450M$398M$345M$297M$246M
EBITDA$39.2M$17.1M-$9.28M-$16.3M-$31.0M
Net income$14.9M-$11.4M-$44.7M-$30.4M-$46.5M
Free cash flow$52.9M$48.3M-$324,000-$7.57M-$39.0M
Capital expenditure$15.6M$9.05M$11.5M$42.0M$16.9M
Total debt$96.8M$76.5M$76.5M$74.5M$71.2M

Quarterly statements and history in the cockpit →

AtriCure competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%COTNCELCOBCK688114AFXIRTCEBO300003MOVE603301002901NEOG688301TMDX603658PLSE300529EKTA-BAXGNATRC6-month return →1-month return →
Up and to the right = strong over both horizons. AtriCure is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×100×200×COTNOBCKAFXIRTCEBOMOVE603301002901688301TMDXEKTA-BAXGNATRCRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. AtriCure is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%OBCK688114AFXIRTCEBO300003603301TMDX603658AXGN688029ATRCGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. AtriCure is the large dot.

AtriCure competitors and peer comparison

Head to head with its named competitors (ATRC vs MDT vs JNJ vs BSX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
AtriCure ATRC$2.82B+91%+14%3%212.4×54.2%
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%
Boston Scientific BSX$63.3B-23%+9%21%14.1×5.8%
Abbott Laboratories ABT$181B+18%+10%14%17.9×16.5%

How AtriCure compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

AtriCure against its 20 peers (data as of 18 Nov 2026)
MeasureATRCPeer medianRank in peer set
1-month return-3.9%-2.5%11th highest of 21
6-month return+91.2%-1.3%highest of 21
Distance from 52-week high-16.0%-30.5%6th highest of 21
Revenue growth (TTM)+13.8%+4.7%6th highest of 20
Operating margin3.1%8.3%6th lowest of 20
Forward P/E212.4×24.4×most expensive of 18
Growth the price implies (Req g, 7 yrs)54.2%11.3%most demanding of 15
Growth delivered (Del g)+20.9%+7.6%3rd highest of 15
Hurdle (Req g minus delivered)+33.2 pp+3.6 pp4th most demanding of 15
ROIC minus cost of capital-7.8 pp-0.7 pp3rd lowest of 19
EV / EBITDA69.7×20.9×most expensive of 9
Net debt / EBITDA-2.3×2.4×least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
AtriCure ATRCUnited States$2.82B+91%+14%3%212.4×54.2%+20.9%
COMET COTN.SWSwitzerland$2.78B-15%-3%6%32.8×n/an/a
Celcuity CELCUnited States$2.73B-60%n/an/an/an/an/a
Ottobock SE & Co. KGaA OBCK.DEGermany$2.65B-30%+5%17%12.3×-1.2%+8.0%
MGI Tech 688114.SSChina$3.06B-4%+2%-7%n/a43.7%-0.1%
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%24.4×12.5%+10.8%
iRhythm IRTCUnited States$3.19B-19%+22%5%99.8×46.9%+23.0%
EBOS EBO.AXAustralia$2.50B+7%+3%3%15.7×4.7%+6.8%
Lepu Medical Technology (Beijing) 300003.SZChina$3.20B-13%-1%13%24.4×8.7%-4.2%
Medacta MOVE.SWSwitzerland$2.48B-28%+8%15%24.0×n/an/a
Zhende Medical 603301.SSChina$3.26B-10%+8%7%42.5×22.9%-16.1%
Double Medical Technology 002901.SZChina$2.43B-2%+13%26%24.2×7.6%+10.4%
Neogen NEOGUnited States$2.42B+25%0%0%32.6×n/an/a
iRay Technology 688301.SSChina$3.31B-30%+58%24%25.7×n/an/a
TransMedics TMDXUnited States$3.35B+42%+28%12%43.4×38.4%+88.2%
Autobio Diagnostics 603658.SSChina$3.36B+16%+3%25%20.3×-0.4%+7.2%
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%n/an/an/a
Jafron Biomedical 300529.SZChina$2.35B+3%+1%37%24.3×6.1%+0.6%
Elekta EKTA-B.STSweden$2.35B0%-7%6%15.3×10.7%+4.0%
Axogen AXGNUnited States$3.40B+33%+24%-5%87.3×52.6%+14.9%
Micro-Tech (Nanjing) 688029.SSChina$2.33B0%+6%18%28.1×11.9%+19.2%

Questions

Who are AtriCure's main competitors?
Named competitors: Medtronic (MDT), Johnson & Johnson (Biosense Webster) (JNJ), Boston Scientific (BSX), Abbott Laboratories (ABT). The cockpit's measured peer set (industry) also includes COMET (COTN.SW), Celcuity (CELC), Ottobock SE & Co. KGaA (OBCK.DE), MGI Tech (688114.SS), Carl Zeiss Meditec (AFX.DE), iRhythm (IRTC).
Is AtriCure expensive compared with its peers?
On forward p/e it trades at 212.4× against a peer median of 24.4×, most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 54% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +33 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has AtriCure stock performed?
Over six months to 18 Nov 2026 the shares returned +91.2% against -1.3% for the median peer; over one year +67.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.